Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ODIN: Optimizing Lymphodepletion in CAR T Cell Therapy for DLBCL
NCT05950802Phase 1Recruiting
- Sponsor
- University Health Network
- Start
- Jul 2023
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of cyclophosphamide in diffuse large B-cell lymphoma (DLBCL) (4 arms), sponsored by University Health Network. Primary endpoint: Safety and tolerability of chemo rads as conditioning chemo at Day 30. Started Jul 2023; status: recruiting.
02
Drugs
cyclophosphamide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05950802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05950802.